Business Context and Reporting Period
This Form 8-K Current Report was filed by Protara Therapeutics, Inc. on January 10, 2022. The filing reports the appointment of Jathin Bandari, M.D., as the Company's Chief Medical Officer, effective January 10, 2022. Dr. Bandari had previously served in various interim and leadership roles within the Company since April 2020.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details.
- Base Salary: $415,000 per year.
- Discretionary Bonus: 40% of base salary.
- Stock Option Grant: 81,000 shares (subject to Board approval).
- Restricted Stock Unit (RSU) Grant: 13,500 shares (subject to Board approval).
Material Changes
The primary material change is the formal appointment of Dr. Bandari as Chief Medical Officer, transitioning him from his role as Interim Chief Medical Officer. This appointment is accompanied by a new Executive Employment Agreement detailing specific compensation and severance terms.
Guidance, Outlook, and Compensation Terms
The filing outlines the following terms under the Executive Employment Agreement:
- Vesting Schedule:
- Stock Options: 25% vests on the first anniversary; the remainder vests monthly over the subsequent 36 months.
- RSUs: Vest in one-third installments annually over three years.
- Severance Provisions: In the event of termination without cause or resignation for good reason, Dr. Bandari is entitled to:
- Accrued base salary through the termination date.
- Nine months of base salary as a lump sum.
- Nine months of target bonus as a lump sum.
- Nine months of healthcare premium reimbursement.
- Pro-rata vesting of equity awards if not employed through the one-year anniversary of the grant date.
- Change in Control: If terminated for reasons other than cause, death, or disability within 18 months of a change in control, 100% of unvested equity awards will accelerate.
The filing notes that the full Executive Employment Agreement will be filed as an exhibit to the Quarterly Report on Form 10-Q for the period ended March 31, 2022.
Investor Verification Checklist
- Verify the final grant date and exercise price for the 81,000 stock options once approved by the Board.
- Confirm the total equity dilution impact of the 81,000 options and 13,500 RSUs relative to the current share count.
- Review the upcoming Form 10-Q for the full text of the Executive Employment Agreement to confirm any additional covenants or conditions.
- Assess the impact of the new CMO appointment on the Company's clinical development pipeline and strategic direction.